Generic placeholder image

Current Cancer Drug Targets


ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Cancer Stem Cells and Epithelial-Mesenchymal Transition: Revisiting Minimal Residual Disease

Author(s): C. Raimondi, W. Gianni, E. Cortesi and P. Gazzaniga

Volume 10, Issue 5, 2010

Page: [496 - 508] Pages: 13

DOI: 10.2174/156800910791517154

Price: $65


The cancer stem cell (CSC) hypothesis provides an attractive model of tumor development and progression, holding that solid tumors are hierarchically organized and sustained by a minority of the tumor cell population with stem cell properties, such as self-renewal, tumorigenicity and multilineage differentiation capacity. Therapeutic resistance, underlying tumor recurrence and the lack of curative treatments in metastatic disease, raise the question if conventional anticancer therapies target the right cells. Indeed, these treatments might miss CSCs, which represent a more chemoresistant and radioresistant subpopulation within cancer. Recently, a direct link between the epithelial-mesenchymal transition process and the gain of stem cell competence were demonstrated in cultured breast cells. In particular, it was shown that the induction of EMT program not only allows cancer cells to disseminate from the primary tumor, but also promotes their self-renewal capability. Furthermore, the expression of stemness and EMT markers in CTCs were associated with resistance to conventional anti-cancer therapies and treatment failure, highlighting the urgency of improving tools for detecting and eliminating minimal residual disease.

Keywords: Cancer stem cells, epithelial-mesenchymal transition, tumor microenvironment

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy